Favorable outcome after 1-year treatment of childhood T-cell lymphoma/T-cell acute lymphoblastic leukemia

Medical and Pediatric Oncology

Volumn 30, Issue 1, 1998, Pages 46-51

  Van Den Berg, Henk ^a   Zsiros, Jószef ^a   Veneberg, Anita ^a   Schutten, Nardi J ^a   Kroes, Wilma ^a   Slater, Rosalyn M ^a   Behrendt, Henk ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Cardiac function; Chemotherapy; Leukemia; Lymphoma; Pulmonary function; T cell

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE FAILURE; HUMAN; INFANT; LUNG INSUFFICIENCY; MALE; PRIORITY JOURNAL; STOMATITIS; T CELL LEUKEMIA; T CELL LYMPHOMA; TREATMENT OUTCOME;

EID: 0030724013     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(199801)30:1<46::AID-MPO12>3.0.CO;2-6     Document Type: Article

References (37)

1. Pui C-H. Behm FG, Crist WM: Clinical and biological relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 82:343-362, 1993.
2. Shuster JJ, Faletta JM, Pullen DJ, et al.: Prognostic factors in childhood T-cell acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood 75:166-173, 1990.
3. Sallan SE, Ritz J, Pesandro J, et al: Cell surface antigens: Prognostic implications in childhood acute lymphoblastic leukemia. Blood 55:395-402, 1980.
4. Pui C-H, Behm FG, Singh B, et al.: Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. Blood 75:174-179, 1990.
5. Crist W, Schuster J, Look T, et al.: Current results of studies of immunophenotype-, age-, and leukocyte-based therapy for children with acute lymphoblastic leukemia. Leukemia 6:162-165, 1992.
6. 2 therapy in 107 children with non-Hodgkin's lymphoma (Burkitt's lymphoma excluded). Cancer 55: 323-336, 1985.
7. 2 with the A-COP + therapeutic regimen: A Pediatric Oncology Group study. J Clin Oncol 6:26-33, 1988.
8. 2 protocol with high dose methotrexate, on 84 children with non-B-cell (lymphoblastic) lymphoma. Med Pediatr Oncol 20:105-113, 1992.
9. Murphy SB: Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: Dissimilarities from lymphomas in adults. Semin Oncol 7:332-339, 1980.
10. Raimondi SC: Current status of cytogenetic research in childhood acute lymphoblastic leukemia. Blood 81:2237-2251, 1993.
11. Steinherz PG, Siegel SE, Bleyer WA, et al.: Lymphomatous presentation of childhood acute lymphoblastic leukemia. Cancer 68: 751-758. 1991.
12. Steinherz PG, Gaynon P, Miller DR, et al.: Improved disease-free survival of children with acute lymphoblastic leukemia - A new intensive therapy protocol: A report from the Childrens Cancer Study Group. J Clin Oncol 4:744-752, 1986.
13. Murphy SB, Aur RJA, Simone JV, et al.: Pretreatment cytokinetic studies in 94 children with acute leukemia. Relationship to other variables at diagnosis and to outcome of standard treatment. Blood 49:683-691, 1977.
14. Pui C-H, Crist WM: Biology and treatment of acute lymphoblastic leukemia. J Pediatr 124:491-503, 1994.
15. Frei E III, Schnabel FM Jr, Goldin A: Comparative chemotherapy of AKR lymphoma and human hematological neoplasia. Cancer Res 34:184-193, 1974.
16. Lauer SJ, Pinkel D, Buchanan GR, et al.: Cytosine arabinoside/ cyclophosphamide pulses during continuation therapy for childhood acute lymphoblastic leukemia; potential selective effect in T-cell leukemia. Cancer 60:2366-2371, 1987.
17. Quddus FF, Leventhal BG, Boyett JM, et al.: Glucocorticoid receptors in immunological subtypes of childhood acute lymphoblastic leukemia cells: A Pediatric Oncology Group study. Cancer Res 45:6482-6486, 1985.
18. Pieters R, Kaspers GJL, Van Wering ER, et al.: Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia. Leukemia 7:392-397, 1993.
19. Magrath IT, Janus C, Edwards BK, et al.: An effective therapy for both undifferentiated (including Burkitt's) lymphoma and lymphoblastic lymphoma's in children and young adults. Blood 63: 1102-1111, 1984.
20. Dahl GV, Rivera G, Pui C-H. et al.: A novel treatment of childhood lymphoblastic non-Hodgkin's lymphoma: Early and intermittent use of teniposide plus cytarabine. Blood 66:1110-1114, 1985.
21. Jones B, Freeman AI, Shuster JJ, et al.: Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol 19:269-275, 1991.
22. Berg H van den, Vet R. Ouden E den, et al.: Significance of lymphoblasts in cerebrospinal fluid in newly diagnosed pediatric acute lymphoblastic malignancies with bone marrow involvement: Possible benefit of dexamethasone. Med Pediatr Oncol 25: 22-27, 1995.
23. Wollner N, Burchenal JH, Lieberman PH, et al.: Non-Hodgkin's lymphoma in children: A comparative study of two modalities of therapy. Cancer 37:123-134, 1976.
24. Tubergen DG, Krailo MD, Meadows AT, et al.: Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: A Childrens Cancer Group study. J Clin Oncol 13: 1368-1376, 1995.
25. Steinherz PG, Gaynon PS, Breneman JC, et al.: Cytoreduction and prognosis in acute lymphoblastic leukemia - The importance of early marrow response: Report from the Childrens Cancer Group. J Clin Oncol 14:389-398, 1996.
26. Schorin MA, Blattner S, Gelber RD, et al.: Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber Cancer Institute/Children's Hospital acute lymphoblastic leukemia consortium protocol 85-01. J Clin Oncol 12:740-747, 1994.
27. Reiter A, Schrappe M, Ludwig W-D, et al.: Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients, results and conclusions of the multicenter trial ALL-BFM 86. Blood 9:3122-3133, 1994.
28. Dowell BL, Borowitz M, Boyett JM, et al.: Immunologic clinicopathologic features of common acute lymphoblastic leukemia antigen-positive childhood T-cell leukemia. A Pediatric Oncology Group study. Cancer 59:2020-2026, 1987.
29. Pui C-H, Rivera GK, Hancock ML, et al.: Clinical significance of CD 10 expression in childhood acute lymphoblastic leukemia. Leukemia 7:35-45, 1993.
30. Speyer JL, Green MD, Kramer E, et al.: Protective effect of the bispiperazinedione ICRF-187 against doxorubicin induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 319:745-752, 1988.
31. Behrendt H, Massar CG, Leeuwen EF van: Mitoxantrone is effective in treating childhood T-cell lymphoma/T-cell acute lymphoblastic leukemia. Cancer 76:339-342, 1995.
32. Mitelman F (ed): "ISCN Guidelines for Cancer Genetics. Supplement to an International System for Human Cytogenetic Nomenclature." Basel: S. Karger, 1991.
33. 2 therapy for childhood advanced lymphoblastic lymphoma. J Clin Oncol 11:2054-2055, 1993.
34. 2 therapy for childhood non-Hodgkin's lymphoma: A report of CCG-551 from the Childrens Cancer Group. J Clin Oncol 11:1024-1032, 1993.
35. Faletta JM, Shuster JJ, Crist WM, et al.: Different patterns of relapse associated with three intensive treatment regimens for pediatric E-rosette positive T-cell leukemia: A Pediatric Oncology Group study. Leukemia 6:541-546, 1992.
36. Rivera GK, Raimondi SC, Hancock ML, et al.: Improved outcome in childhood acute lymphoblastic leukemia with reinforced early treatment and rotational combination chemotherapy. Lancet 337: 61-66, 1991.
37. Clavell LA, Gelber RD, Cohen HJ, et al.: Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 315:657-663, 1986.